A therapeutic cancer vaccine composed of autologous, dendritic cells (DCs) that have been loaded with a proprietary selection of four antigens that covers more than ninety percent of all non-small cell lung cancer (NSCLC) patients, with potential immunostimulatory and antineoplastic activities. Upon administration, autologous tetravalent dendritic cell vaccine MIDRIX4-LUNG may induce and stimulate both T-helper and antigen-specific cytotoxic T-lymphocyte (CTL) responses, leading to tumor cell lysis in patients with NSCLC.